Previous 10 | Next 10 |
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disord...
Looking For The Best Biotech Stocks To Watch This Week? 3 Names To Know Biotech stocks were some of the top performers on the stock market throughout 2020. With the coronavirus vaccine tailwind carrying over to 2021, investors still have their eyes peeled on the industry. Ri...
Have you been looking for stocks that can double your money or better this year? Smart investors know the biotech industry's full of clinical-stage companies that can explode in value overnight in response to positive clinical trial results or Food and Drug Administration approvals. E...
Fate Therapeutics (FATE) commenced an underwritten public offering of $350M of shares.Net proceeds to be used for funding clinical trials and nonclinical studies of its product candidates, the manufacture of its clinical product candidates, the expansion of its cGMP compliant manufacturing op...
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disord...
In our bodies we have cancer-killer cells called "natural killer" cells, or NK cells. These cells are part of our innate immune system. When an NK cell comes across a malign cancer cell in the human body, the NK cell attacks it and destroys it. Scientists believe that this natural cance...
In this video from Motley Fool Live recorded on Dec. 14, Bureau Chief of Healthcare and Cannabis Corinne Cardina and Fool.com contributor Brian Orelli discussed the boost in Fate Therapeutics ' (NASDAQ: FATE) stock price after the biotech presented data on its natural killer (NK...
Fate Therapeutics jumped 9% after ASH and more than quadrupled in 2020. Natural Killer cell therapy FT516 and CAR NK therapy FT596 had positive results. But stock price and market capitalization assume much success based on early data. For further details see: Fate Thera...
Should Investors Be Buying These Biotech Stocks Right Now? Biotech stocks have skyrocketed on the stock market this year. This is definitely no surprise as biotech companies are the leaders in the charge against the coronavirus pandemic. Even in light of Pfizer’s ( ...
Gainers: Obalon Therapeutics (OBLN) +121%.Greenland Technologies (GTEC) +79%.Oncternal Therapeutics (ONCT) +61%.Eastman Kodak (KODK) +60%.Fate Therapeutics (FATE) +46%.Nkarta (NKTX) +44%.Constellation Pharmaceuticals (CNST) +34%.Gamida Cell (GMDA) +31%.EHang Holdings (EH) +30%.Tonix...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...